LONDON - Shionogi & Co., Ltd. (TYO ... oral antiviral candidate targeting Respiratory Syncytial Virus (RSV), conducted by hVIVO plc, a leader in human challenge clinical trials.

(Sharecast News) - hVIVO reported positive results from a phase 2a respiratory syncytial virus (RSV) human challenge trial conducted on behalf of Shionogi on Wednesday. The AIM-traded firm said ...

LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...

The trial demonstrated a significant reduction in viral load for Shionogi's investigational oral RSV antiviral candidate, S-337395. S-337395, which has received Fast Track designation from the U.S ...

RSV patients treated with antiviral drug S-337395 showed statistically significant reduction in viral load S-337395 is ...

Pediatric RSV treatment itself is expected to be a multi-billion-dollar ... oseltamivir (Tamiflu®, Roche), peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche). Additionally, ...

Pediatric RSV treatment itself is expected to be a multi ... peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche). Additionally, NV-387 also demonstrated activity against ...